<SEC-DOCUMENT>0001140361-23-010181.txt : 20230303
<SEC-HEADER>0001140361-23-010181.hdr.sgml : 20230303
<ACCEPTANCE-DATETIME>20230303213032
ACCESSION NUMBER:		0001140361-23-010181
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20230302
FILED AS OF DATE:		20230303
DATE AS OF CHANGE:		20230303

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Kinney Gene G.
		CENTRAL INDEX KEY:			0001564380

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35676
		FILM NUMBER:		23707336

	MAIL ADDRESS:	
		STREET 1:		C/O PROTHENA CORPORATION PLC
		STREET 2:		650 GATEWAY BOULEVARD
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PROTHENA CORP PUBLIC LTD CO
		CENTRAL INDEX KEY:			0001559053
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		77 SIR JOHN ROGERSON'S QUAY, BLOCK C
		STREET 2:		GRAND CANAL DOCKLANDS
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60
		BUSINESS PHONE:		011-353-1-236-2500

	MAIL ADDRESS:	
		STREET 1:		77 SIR JOHN ROGERSON'S QUAY, BLOCK C
		STREET 2:		GRAND CANAL DOCKLANDS
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prothena Corp plc
		DATE OF NAME CHANGE:	20121102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Neotope Corp Ltd
		DATE OF NAME CHANGE:	20120926
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-03-02</periodOfReport>

    <issuer>
        <issuerCik>0001559053</issuerCik>
        <issuerName>PROTHENA CORP PUBLIC LTD CO</issuerName>
        <issuerTradingSymbol>PRTA</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001564380</rptOwnerCik>
            <rptOwnerName>Kinney Gene G.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O PROTHENA BIOSCIENCES INC</rptOwnerStreet1>
            <rptOwnerStreet2>331 OYSTER POINT BOULEVARD</rptOwnerStreet2>
            <rptOwnerCity>SOUTH SAN FRANCISCO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94080</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isOfficer>true</isOfficer>
            <officerTitle>President and CEO</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>52.97</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2023-03-02</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>155000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-03-02</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>155000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>155000</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 2, 2024 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.</footnote>
        <footnote id="F2">The Reporting Person holds options that give him the right to acquire an aggregate of 2,159,700 shares at exercise prices ranging from $12.15 to $52.97, of which 1,642,200 are currently exercisable, and 517,500 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Michael Malecek, as Attorney in Fact for Gene G. Kinney</signatureName>
        <signatureDate>2023-03-03</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
